ivosidenib, MDS, myelodysplastic syndromes, Servier Pharmaceuticals LLC, Tibsovo
Ivosidenib is approved by FDA for myelodysplastic syndromes
Nov 2023: The Food and Drug Administration (FDA) approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in November 2023 for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) who ..
ivosidenib, NCT03173248, Servier Pharmaceuticals LLC, Tibsovo
Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia
June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older with..